New Zealand markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

OTC Markets EXMKT - OTC Markets EXMKT Delayed price. Currency in USD
Add to watchlist
0.00100.0000 (0.00%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 44.57k
Enterprise value 4.85M
Trailing P/E 2.83
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.00
Price/book (mrq)5.40
Enterprise value/revenue 0.25
Enterprise value/EBITDA -0.87

Trading information

Stock price history

Beta (5Y monthly) 1.06
52-week change 3-99.53%
S&P500 52-week change 318.96%
52-week high 30.2327
52-week low 30.0007
50-day moving average 30.0549
200-day moving average 30.0681

Share statistics

Avg vol (3-month) 387.08k
Avg vol (10-day) 326.67k
Shares outstanding 544.57M
Implied shares outstanding 644.57M
Float 837.29M
% held by insiders 118.05%
% held by institutions 110.38%
Shares short (30 Jun 2023) 42M
Short ratio (30 Jun 2023) 40.22
Short % of float (30 Jun 2023) 46.80%
Short % of shares outstanding (30 Jun 2023) 45.55%
Shares short (prior month 31 May 2023) 4439.68k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 3�
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin -5.11%
Operating margin (ttm)-208.39%

Management effectiveness

Return on assets (ttm)-4.40%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)22.36M
Revenue per share (ttm)0.69
Quarterly revenue growth (yoy)4.50%
Gross profit (ttm)N/A
EBITDA -347k
Net income avi to common (ttm)-1.14M
Diluted EPS (ttm)-0.1600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35k
Total cash per share (mrq)0
Total debt (mrq)4.84M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.23
Book value per share (mrq)-0.26

Cash flow statement

Operating cash flow (ttm)-17.89M
Levered free cash flow (ttm)-16.39M